ArticleOncology letters2025
Immunohistochemistry as a reliable predictor of remission in patients with endometrial cancer: Establishment and validation of a machine learning model.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is the most common gynecologic cancer. Unfortunately, its prognosis remains poor due to limited screening and treatment options. To address this issue, the present study evaluated the predictive value of four immunohistochemical (IHC) indicators for overall survival (OS) and recurrence-free survival (RFS) in patients with EC. A total of 834 patients diagnosed with EC were included at Peking University People's Hospital between January 2006 and December 2020. These patients were randomly divided into training and validation cohorts at a 2:1 ratio, collecting data on clinicopathological information and IHC indicators. A total of 92 combinations of algorithms were assessed using the Leave-One-Out Cross-Validation framework to identify the one with the highest C-index. To estimate the accuracy of the factors and four IHC indicators for predicting both OS and RFS, survival curves and receiver operating characteristic (ROC) curves were used. Independent predictors included estrogen receptor, progesterone receptor, body mass index, P53, FIGO stage, histology, grade, Ki67, ascites and lymph node metastasis. Both the training and validation cohorts exhibited excellent predictive performance for OS and RFS, as demonstrated by ROC curves at 1-year, 3-year and 5-year follow-ups. By introducing a model based solely on clinicopathological information as model 1 and adding four IHC indicators in model 2, a significant improvement was observed in the area under the curve (AUC) values across the entire sample. The AUC value for OS curves increased from 0.765 to 0.872, and the AUC for RFS curves rose from 0.791 to 0.882. Thus, the present study's model effectively predicts patients' probability of OS and RFS using these factors. This prediction capability can guide postoperative treatment plans and follow-up intervals, potentially enhancing long-term survival for patients with EC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.